Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D5-2243
- Development stage
- Unknown
- Lead developer
- Zymeworks
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
D5-2243 is a bispecific T-cell engager designed to target HLA-A*02/NY-ESO, an antigen commonly expressed in various advanced solid tumors. The drug functions by redirecting T cells to recognize and kill tumor cells expressing the NY-ESO antigen in the context of HLA-A*02. It is being evaluated as an immunotherapy for patients with advanced solid tumors and represents a novel approach within the field of targeted cancer immunotherapies[1].
02
Targets
CD3 (T-cell surface glycoprotein CD3)HLA class I histocompatibility antigen, A-2 alpha chain/Cancer-testis antigen 1B peptide-MHC complexNY-ESO-1 (New york esophageal squamous cell carcinoma 1)
Beyond the preview
Go deeper on D5-2243.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on D5-2243.